Fig. 1.

Intrathecal injection of gadobutrol in a dose of (a) 0.25 mmol (0.25 ml of 1.0 mmol/ml) or (b) 0.5 mmol (0.50 ml of 1.0 mmol/ml) at the lower lumbar level. Entry of gadobutrol in CSF within the intracranial compartment was preceded by unenhanced T1-weighted MRI (time point “Pre”), and acquisition of identical consecutive T1 scans was initiated immediately and repeated at different time points. Image window/level is adjusted to optimize qualitative illustration of CSF contrast enhancement